Archive for February 2019
FDA Shares New Findings in Valsartan Investigation
The FDA announced that the impurities found in valsartan-containing blood pressure drugs may have been caused by specific chemicals and reaction conditions in the manufacturing process of the drug’s API. Source: Drug GMP Report
Read MoreShutdown That Curtailed Some FDA Inspections Ends – For Now
The FDA reopened on January 25 following a 35-day partial shutdown of the federal government that curtailed the agency’s inspection activities that did not directly tie into public safety. Source: Drug GMP Report
Read More